



Kosei Pharma Foray into Generics

Kosei Pharma invests in generic medicines with a vision to be a generic pharmaceutical manufacturer and prominent player in the pharmaceutical industry by 2018.

Kosei ***Pharma***

The pharmaceutical industry is an important component of the healthcare sector in the United Kingdom. The industry has high growth potential, both in the domestic and export markets, this is in view of its present strength in the production of generic drugs.

The potential of the domestic pharmaceutical industry has been recognised by the government which has identified it as a strategic industry which should be promoted.

Launching in May/June 2017

Branded pharmaceutical companies invest significant amounts of money in researching and developing new drugs. These new drugs enjoy patent protection for up to 20 years, which gives the manufacturer the exclusive right to market and sell their drug, and to receive a return on their original R&D investment. Once the patents on these new drugs expire, other drug companies can apply to manufacture a generic (bioequivalent) product. As more companies manufacture the drug, increased competition drives down the price to customers and in turn, the cost to the NHS.

As a result of the Patent Protection having expired on a number of high value high volume products over the previous 5 years, coupled with an increase in prescription numbers, we are seeing a year on year increase in Generic production and dispensing within the UK healthcare market.

This in turn is helping to drive costs down and enable the NHS to supply equivalent drugs to the patients whilst making a saving versus the Ethical Product.

The UK has some, if not the lowest overall pricing of generics within the EU. This is being driven by the competitive nature of the UK market in comparison with the rest of the EU.

Whilst the Generic market is an extremely competitive area, it is also a growth area within the UK healthcare market. The continuing increase of prescriptions along with an growing population show that the market will continue to grow.

With the combination of more Generic products, an increase in generically written prescriptions and a highly competitive generics market, National Health Authorities are able to drive both efficiency and financial savings over the coming years. Whilst this will not mitigate the cuts that are happening, it will help to soften the blow to a degree.

FREEPHONE: 0800 193 5051
WWW.KOSEIPHARMA.COM